A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer
Authors
Keywords
-
Journal
Translational Oncology
Volume 33, Issue -, Pages 101670
Publisher
Elsevier BV
Online
2023-04-13
DOI
10.1016/j.tranon.2023.101670
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- (2022) Ruidong Li et al. CANCER RESEARCH
- NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition
- (2022) Sepideh Mirzaei et al. JOURNAL OF CELLULAR PHYSIOLOGY
- PFKL, a novel regulatory node for NOX2-dependent oxidative burst and NETosis
- (2022) Zhaohui Cao et al. Journal of Zhejiang University-SCIENCE B
- Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1
- (2022) Jack Lawler SEMINARS IN CANCER BIOLOGY
- Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
- (2022) Enrique A. Castellón et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
- (2021) Alexander Bagaev et al. CANCER CELL
- Selective activation of PFKL suppresses the phagocytic oxidative burst
- (2021) Neri Amara et al. CELL
- m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
- (2020) Huilin Huang et al. CANCER CELL
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
- (2020) David A. Braun et al. NATURE MEDICINE
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- MODOMICS: a database of RNA modification pathways. 2017 update
- (2017) Pietro Boccaletto et al. NUCLEIC ACIDS RESEARCH
- Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
- (2017) Martin Lauss et al. Nature Communications
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
- (2017) Shuang G. Zhao et al. JAMA Oncology
- Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway
- (2016) Selvi Ramasamy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling
- (2014) Eric A. Klein et al. EUROPEAN UROLOGY
- Gene expression regulation mediated through reversible m6A RNA methylation
- (2014) Ye Fu et al. NATURE REVIEWS GENETICS
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and validation of a 32-gene prognostic index for prostate cancer progression
- (2013) C.-L. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer
- (2011) Kathryn L. Penney et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started